Telisotuzumab vedotin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | c-Met |
| Clinical data | |
| Trade names | Emrelis |
| Other names | ABBV-399, telisotuzumab vedotin-tllv |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
| KEGG | |
Telisotuzumab vedotin, sold under the brand name Emrelis, is an antibody drug conjugate used for the treatement of non-small cell lung cancer.[1] Telisotuzumab vedotin is a c-Met-directed antibody and microtubule inhibitor conjugate.[1] It was developed by AbbVie.
The most common adverse reactions include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.[2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin, and decreased calcium.[2]
Telisotuzumab vedotin was approved for medical use in the United States in May 2025.[2][3]
- ^ a b c "Highlights of prescribing information - EMRELISTM (telisotuzumab vedotin-tllv) for injection" (PDF). Archived from the original (PDF) on 28 July 2025.
- ^ a b c "FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression". U.S. Food and Drug Administration. 14 May 2025. Archived from the original on 16 May 2025. Retrieved 30 May 2025. This article incorporates text from this source, which is in the public domain.
- ^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 29 May 2025. Archived from the original on 3 March 2025. Retrieved 29 May 2025. This article incorporates text from this source, which is in the public domain.